相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Chemotherapy sensitization of glioblastoma by focused ultrasound-mediated delivery of therapeutic liposomes
Alexandros Papachristodoulou et al.
JOURNAL OF CONTROLLED RELEASE (2019)
Overview of DNA methylation in adult diffuse gliomas
Kosuke Aoki et al.
BRAIN TUMOR PATHOLOGY (2019)
Posttreatment Effect of MGMT Methylation Level on Glioblastoma Survival
Rikke H. Dahlrot et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2019)
DNA repair in personalized brain cancer therapy with temozolomide and nitrosoureas
Bernd Kaina et al.
DNA REPAIR (2019)
Gene promoter methylation and cancer: An umbrella review
Emmanouil Bouras et al.
GENE (2019)
Clinical and Prognostic Significance of O6-Methylguanine-DNA Methyltransferase Promoter Methylation in Patients with Melanoma: A Systematic Meta-Analysis
Fang Qi et al.
ANNALS OF DERMATOLOGY (2018)
Outlining involvement of stem cell program in regulation of O6-methylguanine DNA methyltransferase and development of temozolomide resistance in glioblastoma: An Editorial Highlight for 'Transcriptional control of O6-methylguanine DNA methyltransferase expression and temozolomide resistance in glioblastoma' on page 780
Anastasia Chumakova et al.
JOURNAL OF NEUROCHEMISTRY (2018)
Transcriptional control of O6-methylguanine DNA methyltransferase expression and temozolomide resistance in glioblastoma
Caroline Happold et al.
JOURNAL OF NEUROCHEMISTRY (2018)
Repair gene O-6-methylguanine-DNA methyltransferase is controlled by SP1 and up-regulated by glucocorticoids, but not by temozolomide and radiation
Dorthe Aasland et al.
JOURNAL OF NEUROCHEMISTRY (2018)
MGMT promoter methylation is not correlated with integrin expression in malignant gliomas: clarifying recent clinical trial results
Oliver Schnell et al.
MEDICAL ONCOLOGY (2018)
MGMT assessment in pituitary adenomas: comparison of different immunohistochemistry fixation chemicals
Alexander S. G. Micko et al.
PITUITARY (2018)
Concordant association validates MGMT methylation and protein expression as favorable prognostic factors in glioma patients on alkylating chemotherapy (Temozolomide)
Arshad A. Pandith et al.
SCIENTIFIC REPORTS (2018)
Epigenetic Targeting of Glioblastoma
Massimo Romani et al.
FRONTIERS IN ONCOLOGY (2018)
MiR-198 enhances temozolomide sensitivity in glioblastoma by targeting MGMT
Er Nie et al.
JOURNAL OF NEURO-ONCOLOGY (2017)
Comparative assessment of three methods to analyze MGMT methylation status in a series of 350 gliomas and gangliogliomas
Leiming Wang et al.
PATHOLOGY RESEARCH AND PRACTICE (2017)
Uptake of glucose-conjugated MGMT inhibitors in cancer cells: role of flippases and type IV P-type ATPases
Karl-Heinz Tomaszowski et al.
SCIENTIFIC REPORTS (2017)
Corticosteroids compromise survival in glioblastoma
Kenneth L. Pitter et al.
BRAIN (2016)
MGMT promoter methylation determined by HRM in comparison to MSP and pyrosequencing for predicting high-grade glioma response
Olivier J. Switzeny et al.
CLINICAL EPIGENETICS (2016)
Impact on prognosis of the regional distribution of MGMT methylation with respect to the CpG island methylator phenotype and age in glioma patients
Pilar Mur et al.
JOURNAL OF NEURO-ONCOLOGY (2015)
Multidrug Efflux Pumps Attenuate the Effect of MGMT Inhibitors
Karl-Heinz Tomaszowski et al.
MOLECULAR PHARMACEUTICS (2015)
Apoptosis induced by temozolomide and nimustine in glioblastoma cells is supported by JNK/c-Jun-mediated induction of the BH3-only protein BIM
Maja T. Tomicic et al.
ONCOTARGET (2015)
Disulfiram is a direct and potent inhibitor of human O6-methylguanine-DNA methyltransferase (MGMT) in brain tumor cells and mouse brain and markedly increases the alkylating DNA damage
Ameya Paranjpe et al.
CARCINOGENESIS (2014)
MGMT promoter methylation and correlation with protein expression in primary central nervous system lymphoma
L. Toffolatti et al.
VIRCHOWS ARCHIV (2014)
Transcriptional/epigenetic regulator CBP/p300 in tumorigenesis: structural and functional versatility in target recognition
Feng Wang et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2013)
O6-methylguanine-DNA methyltransferase (MGMT) immunohistochemistry as a predictor of resistance to temozolomide in primary CNS lymphoma
Xiaoyin Jiang et al.
JOURNAL OF NEURO-ONCOLOGY (2013)
YB-1 dependent oncolytic adenovirus efficiently inhibits tumor growth of glioma cancer stem like cells
Klaus Mantwill et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2013)
MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status
Pierre Bady et al.
ACTA NEUROPATHOLOGICA (2012)
Predictive impact of MGMT promoter methylation in glioblastoma of the elderly
Guido Reifenberger et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
MGMT testing for glioma in clinical laboratories: discordance with methylation analyses prevents the implementation of routine immunohistochemistry
Sofia Mason et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2012)
Oncolytic Virus-Mediated Manipulation of DNA Damage Responses: Synergy With Chemotherapy in Killing Glioblastoma Stem Cells
Ryuichi Kanai et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy
Consolacion Melguizo et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2012)
Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial
Annika Malmstrom et al.
LANCET ONCOLOGY (2012)
Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial
Wolfgang Wick et al.
LANCET ONCOLOGY (2012)
miR-181d: a predictive glioblastoma biomarker that downregulates MGMT expression
Wei Zhang et al.
NEURO-ONCOLOGY (2012)
A distinct region of the MGMT CpG island critical for transcriptional regulation is preferentially methylated in glioblastoma cells and xenografts
Deborah S. Malley et al.
ACTA NEUROPATHOLOGICA (2011)
Inhibition of DNA repair with MGMT pseudosubstrates: phase I study of lomeguatrib in combination with dacarbazine in patients with advanced melanoma and other solid tumours
H. A. Tawbi et al.
BRITISH JOURNAL OF CANCER (2011)
Correlation of MGMT promoter methylation status with gene and protein expression levels in glioblastoma
Miyuki Uno et al.
CLINICS (2011)
Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas
Joerg Felsberg et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
RTOG 0525: A randomized phase III trial comparing standard adjuvant temozolomide (TMZ) with a dose-dense (dd) schedule in newly diagnosed glioblastoma (GBM).
M. R. Gilbert et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Tumor O6-methylguanine-DNA Methyltransferase Inactivation by Oral Lomeguatrib
Amanda J. Watson et al.
CLINICAL CANCER RESEARCH (2010)
Efficient delivery of liposome-mediated MGMT-siRNA reinforces the cytotoxity of temozolomide in GBM-initiating cells
T. Kato et al.
GENE THERAPY (2010)
MGMT activity, promoter methylation and immunohistochemistry of pretreatment and recurrent malignant gliomas: a comparative study on astrocytoma and glioblastoma
Markus Christmann et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
O-6-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implications
Alba A. Brandes et al.
NEURO-ONCOLOGY (2010)
Intratumoral Hypoxic Gradient Drives Stem Cells Distribution and MGMT Expression in Glioblastoma
Francesca Pistollato et al.
STEM CELLS (2010)
O6-methylguanine-DNA methyltransferase depletion and DNA damage in patients with melanoma treated with temozolomide alone or with lomeguatrib
A. J. Watson et al.
BRITISH JOURNAL OF CANCER (2009)
Phase II Trial of Gliadel plus O6-Benzylguanine in Adults with Recurrent Glioblastoma Multiforme
Jennifer A. Quinn et al.
CLINICAL CANCER RESEARCH (2009)
MGMT Promoter Methylation Is Prognostic but Not Predictive for Outcome to Adjuvant PCV Chemotherapy in Anaplastic Oligodendroglial Tumors: A Report From EORTC Brain Tumor Group Study 26951
Martin J. van den Bent et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase II Trial of Temozolomide Plus O6-Benzylguanine in Adults With Recurrent, Temozolomide-Resistant Malignant Glioma
Jennifer A. Quinn et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
NOA-04 Randomized Phase III Trial of Sequential Radiochemotherapy of Anaplastic Glioma With Procarbazine, Lomustine, and Vincristine or Temozolomide
Wolfgang Wick et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma
Jennifer A. Quinn et al.
NEURO-ONCOLOGY (2009)
Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas
Sibille Everhard et al.
NEURO-ONCOLOGY (2009)
Anti-O6-methylguanine-methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: Observer variability and lack of association with patient survival impede its use as clinical biomarker
Matthias Preusser et al.
BRAIN PATHOLOGY (2008)
O6-Methylguanine-DNA methyltransferase inactivation and chemotherapy
Barbara Verbeek et al.
BRITISH MEDICAL BULLETIN (2008)
Temozolomide preferentially depletes cancer stem cells in glioblastoma
Dagmar Beier et al.
CANCER RESEARCH (2008)
MGMT in primary and recurrent human glioblastomas after radiation and chemotherapy and comparison with p53 status and clinical outcome
Dorothee Wiewrodt et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Relevance of MSP assay for the detection of MGMT promoter hypermethylation in glioblastomas
Kazunari Yachi et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2008)
Adenovirus-based strategies overcome temozolomide resistance by silencing the O6-methylguanine-DNA methyltransferase promoter
Marta M. Alonso et al.
CANCER RESEARCH (2007)
Phase I trial of single-dose temozolomide and continuous administration of O6-benzylguanine in children with brain tumors:: a Pediatric Brain Tumor Consortium report
Alberto Broniscer et al.
CLINICAL CANCER RESEARCH (2007)
Inactivation of O6-Alkylguanine-DNA alkyltransferase by folate esters of O6-Benzyl-2'-deoxyguanosine and of O6-[4-(Hydroxymethyl)benzyl]guanine
Sahar Javanmard et al.
JOURNAL OF MEDICINAL CHEMISTRY (2007)
MGMT prognostic impact on glioblastoma is dependent on therapeutic modalities
Emmanuelle Criniere et al.
JOURNAL OF NEURO-ONCOLOGY (2007)
CD133+ and CD133- glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles
Dagmar Beier et al.
CANCER RESEARCH (2007)
Local intracerebral administration of O6-benzylguanine combined with systemic chemotherapy with temozolomide of a patient suffering from a recurrent glioblastoma
Dorothee Koch et al.
JOURNAL OF NEURO-ONCOLOGY (2007)
Analysis of gene expression and chemoresistance of CDI33+ cancer stem cells in glioblastoma
Gentao Liu et al.
MOLECULAR CANCER (2006)
MGMT methylation:: A marker of response to temozolomide in low-grade gliomas
Sibille Everhard et al.
ANNALS OF NEUROLOGY (2006)
Oncolytic viruses and DNA-repair machinery: overcoming chemoresisfance of gliomas
Hong Jiang et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2006)
Serial pyrosequencing for quantitative DNA methylation analysis
J Tost et al.
BIOTECHNIQUES (2006)
O6-(4-Bromothenyl)guanine (PaTrin-2), a novel inhibitor of O6-alkylguanine DNA alkyl-transferase, increases the inhibitory activity of temozolomide against human acute leukaemia cells in vitro
M Turriziani et al.
PHARMACOLOGICAL RESEARCH (2006)
Lomeguatrib, a potent inhibitor of O6-alkylguanine-DNA-alkyltransferase:: Phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors
M Ranson et al.
CLINICAL CANCER RESEARCH (2006)
O6-(4-bromothenyl)guanine reverses temozolomide resistance in human breast tumour MCF-7 cells and xenografts
M Clemons et al.
BRITISH JOURNAL OF CANCER (2005)
Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma
JA Quinn et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
O6-methylguanine-DNA methyltransferase, O6-benzylguanine, and resistance to clinical alkylators in pediatric primary brain tumor cell lines
MS Bobola et al.
CLINICAL CANCER RESEARCH (2005)
MGMT gene silencing and benefit from temozolomide in glioblastoma
ME Hegi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
NCBI Reference Sequence (RefSeq): a curated non-redundant sequence database of genomes, transcripts and proteins
KD Pruitt et al.
NUCLEIC ACIDS RESEARCH (2005)
Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide
ME Hegi et al.
CLINICAL CANCER RESEARCH (2004)
Inhibition of O6-methylguanine-DNA methyltransferase by glucose-conjugated inhibitors:: Comparison with nonconjugated inhibitors and effect on fotemustine and temozolomide-induced cell death
B Kaina et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2004)
Improvement of chemotherapy efficacy by inactivation of a DNA-repair pathway
MR Middleton et al.
LANCET ONCOLOGY (2003)
BLAT - The BLAST-like alignment tool
WJ Kent
GENOME RESEARCH (2002)
Inactivation of O6-methylguanine-DNA methyltransferase by glucose-conjugated inhibitors
J Reinard et al.
INTERNATIONAL JOURNAL OF CANCER (2001)
Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents
M Esteller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Regulation of the human O6-methylguanine-DNA methyltransferase gene by transcriptional coactivators cAMP response element-binding protein-binding protein and p300
KK Bhakat et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
分享论文
